The effects of 17β-oestradiol on increased α1- adrenergic vascular reactivity induced by prolonged ovarian hormone deprivation: The role of voltage-dependent l-type ca channels

Pharmacology

Volumn 90, Issue 5-6, 2012, Pages 316-323

  Valencia Hernández, Ignacio ^c   Reyes Ramírez, José Antonio ^c   Urquiza Marín, Héctor ^a   Nateras Marín, Blanca ^a   Villegas Bedolla, José Carlos ^a,b   Godínez Hernández, Daniel ^a  

^a Instituto de Investigaciones Químico Biológicas de la UMSNH   (Mexico)

^b UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

1 Adrenergic agonists; 1 Adrenergic receptors; 17 Oestradiol; Calcium ion; ICI 182,780; L type voltage Ca2+ channels; Oestrogen receptors; Ovariectomy; Phenylephrine; Vascular reactivity

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CALCIUM CHANNEL L TYPE; CALCIUM ION; CORN OIL; ESTRADIOL; PHENYLEPHRINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ESTRADIOL BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HORMONE DEFICIENCY; NONHUMAN; OVARIAN HORMONE DEPRIVATION; OVARIECTOMY; OVARY; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; TREATMENT DURATION; VASCULAR RING; VASOCONSTRICTION;

ANIMALS; AORTA, THORACIC; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; ESTRADIOL; ESTROGENS; FEMALE; OVARIECTOMY; PHENYLEPHRINE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VERAPAMIL;

EID: 84866925780     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000342635     Document Type: Article

References (31)

1. Yang XP, R eckelhoff JF: Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens 2011;20: 133-138.
2. Xing D, Nozell S, Chen YF, Hage F, Oparil S: Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009; 29:289-295.
3. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523-534. (Pubitemid 36951364)
4. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D: Noncardiovascular disease outcomes during 6. years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66. (Pubitemid 34705519)
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ Progestin Replacement Study (HERS) research group. JAMA 1998;280:605-613. (Pubitemid 28502636)
6. Tepareenan P, Kendall DA, Randall MD: Mechanisms of vasorelaxation to 17betaoestradiol in rat arteries. Eur J Pharmacol 2003;476:139-149. (Pubitemid 37315546)
7. Lee HA, Seong Y, Lee WJ, Kim I: 17Beta-estradiol inhibits calcium-dependent, but not calcium-independent, contraction in isolated rat aorta. Naunyn Schmiedebergs Arch Pharmacol 2005;371:152-157. (Pubitemid 40487420)
8. Barkhem T, Nilsson S, Gustafsson JA: Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenom 2004;4:19-28. (Pubitemid 38325702)
9. Ruehlmann DO, Mann GE: Rapid non-genomic vasodilator actions of oestrogens and sex steroids. Curr Med Chem 2000;7:533-541. (Pubitemid 30396427)
10. Babiker FA, De Windt LJ, van Eickels M, Grohe C, Meyer R, Doevendans PA: Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res 2002;53:709-719. (Pubitemid 34175263)
11. Prossnitz ER, Maggiolini M: Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 2009;308:32-38.
12. Kuo J, Micevych P: Neurosteroids, trigger of the LH surge. J Steroid Biochem Mol Biol 2012;131:57-65.
13. Zamorano B, Bruzzone ME, Martinez JL: Vascular smooth muscle reactivity to norepinephrine in ovariectomized rats: relationship to vascular PGE2/PGF2 alpha ratio. Gen Pharmacol 1995;26:1613-1618. (Pubitemid 26011511)
14. Crews JK, Khalil RA: Gender-specific inhibition of Ca2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol 1999;26:707-715. (Pubitemid 29437242)
15. Mehrotra S, Gupta S, Villalon CM, Boomsma F, Saxena PR, Maassen-Van den Brink A: Rat carotid artery responses to alpha-adrenergic receptor agonists and 5-HT after ovariectomy and hormone replacement. Headache 2007;47:236-246.
16. Paden CM, McEwen BS, Fishman J, Snyder L, De Groff V: Competition by estrogens for catecholamine receptor binding in vitro. J Neurochem 1982;39:512-520. (Pubitemid 12013631)
17. Zang WJ, Zacharia J, Lamont C, Wier WG: Sympathetically evoked Ca2+ signaling in arterial smooth muscle. Acta Pharmacol Sin 2006;27:1515-1525. (Pubitemid 44813887)
18. Docherty JR: Subtypes of functional alpha1- adrenoceptor. Cell Mol Life Sci 2010;67: 405-417.
19. Ullrich ND, Koschak A, MacLeod KT: Oestrogen directly inhibits the cardiovascular L-type Ca2+ channel CAV1. Biochem Biophys Res Commun 2007;361:522-527. (Pubitemid 47187289)
20. Nakajima T, Kitazawa T, Hamada E, Hazama H, Omata M, Kurachi Y: 17Beta-estradiol inhibits the voltage-dependent L-type Ca2+ currents in aortic smooth muscle cells. Eur J Pharmacol 1995;294:625-635. (Pubitemid 26016768)
21. Chiu AT, McCall DE, Timmermans PB: Pharmacological characteristics of receptor-operated and potential-operated Ca2+ channels in rat aorta. Eur J Pharmacol 1986;127:1-8. (Pubitemid 16023604)
22. Gonzalez-Arenas A, Aguilar-Maldonado B, Avendano-Vazquez SE, Garcia-Sainz JA: Estrogens cross-talk to alpha1b-adrenergic receptors. Mol Pharmacol 2006;70:154-162.
23. Perez-Lopez FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS: Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 2010;17: 511-531.
24. Mendelsohn ME, Karas RH: Rapid progress for non-nuclear estrogen receptor signaling. J Clin Invest 2010;120:2277-2279.
25. Enkhjargal B, Hashimoto M, Kinoshita H, Sakai Y: Characteristics of contractile activity in the renal artery of ovariectomized rats. J Smooth Muscle Res 2008;44:17-28.
26. Zhang Y, Davidge ST: Effect of estrogen replacement on vasoconstrictor responses in rat mesenteric arteries. Hypertension 1999; 34:1117-1122.
27. Andersen HL, Weis JU, Fjalland B, Korsgaard N: Effect of acute and long-term treatment with 17-beta-estradiol on the vasomotor responses in the rat aorta. Br J Pharmacol 1999;126:159-168. (Pubitemid 29041755)
28. Villalobos-Molina R, Ibarra M: Increased expression and function of vascular alpha1dadrenoceptors may mediate the prohypertensive effects of angiotensin II. Mol Interv 2005;5:340-342. (Pubitemid 43060714)
29. Garcia-Sainz JA, Villalobos-Molina R: The elusive alpha(1d)-adrenoceptor: molecular and cellular characteristics and integrative roles. Eur J Pharmacol 2004;500:113-120. (Pubitemid 39304001)
30. Bowling N, Bloomquist WE, Cohen ML, Bryant HU, Cole HW, Magee DE, Rowley ER, Vlahos CJ: Effects of prolonged ethinyl estradiol treatment on calcium channel binding and in vivo calcium-mediated hemodynamic responses in ovariectomized rats. J Pharmacol Exp Ther 1997;281:218-225. (Pubitemid 27203071)
31. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238. (Pubitemid 36828445)